| Assessment Status | Rapid Review Complete |
| HTA ID | 24007 |
| Drug | Rezafungin |
| Brand | Rezzayo® |
| Indication | Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults. |
| Assessment Process | |
| Rapid review commissioned | 22/03/2024 |
| Rapid review completed | 26/03/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that rezafungin not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
